XM无法为美国居民提供服务。
S
S

Sanofi

交易方向

交易者偏好

技术摘要

每小时

市场新闻

France seeks job guarantees from Sanofi over Doliprane painkiller production

UPDATE 1-France seeks job guarantees from Sanofi over Doliprane painkiller production Adds quotes, details, background throughout PARIS, Oct 14 (Reuters) - The French government needs guarantees from drugmaker Sanofi SASY.PA that production of its popular Doliprane painkiller will stay in France to allow the sale of its consumer health branch to go ahead, Economy Minister Antoine Armand said on Monday.
S

French government seeking job guarantees from Sanofi over Doliprane production sites

French government seeking job guarantees from Sanofi over Doliprane production sites PARIS, Oct 14 (Reuters) - The French government is seeking job guarantees from drugmaker Sanofi SASY.PA regarding its Doliprane production sites in the event of a sale of its consumer health branch, Economy Minister Antoine Armand said on Monday. On Friday, Sanofi said it had entered talks to sell a controlling 50% stake in its Opella business - whose brands include Doliprane - to U.S.
S

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds: CVS, Frasers Group, Tetragon, Oct 11 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Friday: * * CVS Health CVS.N is exiting its core infusion services business and plans to either close or sell 29 related regional pharmacies in the coming months, a company spokesperson confirmed to Reuters on Friday.
A
A
B
S
U

US FDA approves Pfizer's drug for rare bleeding disorder

UPDATE 2-US FDA approves Pfizer's drug for rare bleeding disorder Adds analyst estimates in paragraph 6, trial details in paragraph 8, and other treatments in paragraph 5, 10 and 11 By Sruthi Narasimha Chari and Christy Santhosh Oct 11 (Reuters) - The U.S. Food and Drug Administration approved Pfizer's PFE.N once-a-week injection for the two main types of a rare bleeding disorder called hemophilia, the company said on Friday.
B
P
S

US FDA approves Pfizer's drug for rare bleeding disorder

US FDA approves Pfizer's drug for rare bleeding disorder Oct 11 (Reuters) - The U.S. Food and Drug Administration approved Pfizer's PFE.N once-a-week injection for the two main types of a rare bleeding disorder called hemophilia, the company said on Friday. Reporting by Sruthi Narasimha Chari and Christy Santhosh in Bengaluru; Editing by Vijay Kish
B
P
S

商品详情

热门商品

免责声明: XM Group仅提供在线交易平台的执行服务和访问权限,并允许个人查看和/或使用网站或网站所提供的内容,但无意进行任何更改或扩展,也不会更改或扩展其服务和访问权限。所有访问和使用权限,将受下列条款与条例约束:(i) 条款与条例;(ii) 风险提示;以及(iii) 完整免责声明。请注意,网站所提供的所有讯息,仅限一般资讯用途。此外,XM所有在线交易平台的内容并不构成,也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。

所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。

本网站上由XM和第三方供应商所提供的所有内容,包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接,皆保持不变,并作为一般市场评论所提供,而非投资性建议。所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为适用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解,XM非独立投资研究提示和风险提示相关资讯,更多详情请点击 这里

风险提示: 您的资金存在风险。杠杆商品并不适合所有客户。请详细阅读我们的风险声明